<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39379400</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-0105</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>NPJ vaccines</Title><ISOAbbreviation>NPJ Vaccines</ISOAbbreviation></Journal><ArticleTitle>Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens.</ArticleTitle><Pagination><StartPage>184</StartPage><MedlinePgn>184</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">184</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41541-024-00982-1</ELocationID><Abstract><AbstractText>We previously described a two-component protein nanoparticle vaccine platform that displays 60 copies of the SARS-CoV-2 spike protein RBD (RBD-NP). The vaccine, when adjuvanted with AS03, was shown to elicit robust neutralizing antibody and CD4 T cell responses in Phase I/II clinical trials, met its primary co-endpoints in a Phase III trial, and has been licensed by multiple regulatory authorities under the brand name SKYCovione<sup>TM</sup>. Here we characterize the biophysical properties, stability, antigenicity, and immunogenicity of RBD-NP immunogens incorporating mutations from the B.1.351 (β) and P.1 (γ) variants of concern (VOCs) that emerged in 2020. We also show that the RBD-NP platform can be adapted to the Omicron strains BA.5 and XBB.1.5. We compare β and γ variant and E484K point mutant nanoparticle immunogens to the nanoparticle displaying the Wu-1 RBD, as well as to soluble prefusion-stabilized (HexaPro) spike trimers harboring VOC-derived mutations. We find the properties of immunogens based on different SARS-CoV-2 variants can differ substantially, which could affect the viability of variant vaccine development. Introducing stabilizing mutations in the linoleic acid binding site of the RBD-NPs resulted in increased physical stability compared to versions lacking the stabilizing mutations without deleteriously affecting immunogenicity. The RBD-NP immunogens and HexaPro trimers, as well as combinations of VOC-based immunogens, elicited comparable levels of neutralizing antibodies against distinct VOCs. Our results demonstrate that RBD-NP-based vaccines can elicit neutralizing antibody responses against SARS-CoV-2 variants and can be rapidly designed and stabilized, demonstrating the potential of two-component RBD-NPs as a platform for the development of broadly protective coronavirus vaccines.</AbstractText><CopyrightInformation>© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Miranda</LastName><ForeName>Marcos C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-2839-6997</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kepl</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>Mary Jane</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chengbo</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3459-3655</Identifier><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biological Physics Structure and Design Program, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Max</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sprouse</LastName><ForeName>Kaitlin R</ForeName><Initials>KR</Initials><Identifier Source="ORCID">0000-0003-0007-2226</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Cameron</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palser</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Kymab Ltd., Babraham Research Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valdez</LastName><ForeName>Adian</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0007-3772-9646</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pettie</LastName><ForeName>Deleah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sydeman</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogohara</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraft</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Minh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wrenn</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiala</LastName><ForeName>Brooke</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravichandran</LastName><ForeName>Rashmi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corti</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vir Biotechnology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellam</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Kymab Ltd., Babraham Research Campus, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biological Physics Structure and Design Program, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walls</LastName><ForeName>Alexandra C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veesler</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA. dveesler@uw.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA. dveesler@uw.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Neil P</ForeName><Initials>NP</Initials><Identifier Source="ORCID">0000-0002-2978-4692</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA. neilking@uw.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Protein Design, University of Washington, Seattle, WA, USA. neilking@uw.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM120553</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 AI158186</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>INV-010680</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI167966</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN272201700059C</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AI167966</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Vaccines</MedlineTA><NlmUniqueID>101699863</NlmUniqueID><ISSNLinking>2059-0105</ISSNLinking></MedlineJournalInfo><CoiStatement>A.C.W., D.E., D.V., and N.P.K. are named as inventors on patent applications filed by the University of Washington based on the studies presented in this paper. The King lab has received unrelated sponsored research agreements from Pfizer and GSK. D.V. is a consultant for and has received an unrelated sponsored research agreement from Vir Biotechnology Inc. P.K. and A.P. were employees and shareholders of Kymab Ltd, now Kymab, a Sanofi Company. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39379400</ArticleId><ArticleId IdType="pmc">PMC11461925</ArticleId><ArticleId IdType="doi">10.1038/s41541-024-00982-1</ArticleId><ArticleId IdType="pii">10.1038/s41541-024-00982-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Novel Coronavirus – China. https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON233.</Citation></Reference><Reference><Citation>Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature586, 567–571 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7581537</ArticleId><ArticleId IdType="pubmed">32756549</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature586, 578–582 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8436420</ArticleId><ArticleId IdType="pubmed">32731258</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature592, 616–622 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8503938</ArticleId><ArticleId IdType="pubmed">33567448</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature592, 438–443 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33690265</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell184, 2348–2361.e6 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901269</ArticleId><ArticleId IdType="pubmed">33730597</ArticleId></ArticleIdList></Reference><Reference><Citation>Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa. Nature603, 679–686 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942855</ArticleId><ArticleId IdType="pubmed">35042229</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, G. &amp; Moriyama, E. N. 2019nCoVR-A comprehensive genomic resource for SARS-CoV-2 variant surveillance. Innovation (Camb.)2, 100150 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8357486</ArticleId><ArticleId IdType="pubmed">34401863</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants.</Citation></Reference><Reference><Citation>Gagne, M. et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell185, 1556–1571.e18 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8947944</ArticleId><ArticleId IdType="pubmed">35447072</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett, K. S. et al. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. Science374, 1343–1353 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34672695</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell183, 1367–1382.e17 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7604136</ArticleId><ArticleId IdType="pubmed">33160446</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam, P. S. et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature594, 253–258 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33873199</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, J. Y. et al. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial. eClinicalMedicine64, 102140 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10498190</ArticleId><ArticleId IdType="pubmed">37711219</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, J. Y. et al. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. EClinicalMedicine51, 101569 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9304916</ArticleId><ArticleId IdType="pubmed">35879941</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls, A. C. et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell184, 5432–5447.e16 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440233</ArticleId><ArticleId IdType="pubmed">34619077</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, A. A. et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science377, eabq0839 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9273039</ArticleId><ArticleId IdType="pubmed">35857620</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, A. A. et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science371, 735–741 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928838</ArticleId><ArticleId IdType="pubmed">33436524</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh, C.-L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science369, 1501–1505 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402631</ArticleId><ArticleId IdType="pubmed">32703906</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis, D. et al. Stabilization of the SARS-CoV-2 spike receptor-binding domain using deep mutational scanning and structure-based design. Front. Immunol.12, 710263 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8276696</ArticleId><ArticleId IdType="pubmed">34267764</ArticleId></ArticleIdList></Reference><Reference><Citation>Bale, J. B. et al. Accurate design of megadalton-scale two-component icosahedral protein complexes. Science353, 389–394 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5485857</ArticleId><ArticleId IdType="pubmed">27463675</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr, T. N., Greaney, A. J., Dingens, A. S. &amp; Bloom, J. D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep. Med.2, 100255 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8020059</ArticleId><ArticleId IdType="pubmed">33842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science368, 630–633 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164391</ArticleId><ArticleId IdType="pubmed">32245784</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones, B. E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci. Transl. Med.13, eabf1906 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8284311</ArticleId><ArticleId IdType="pubmed">33820835</ArticleId></ArticleIdList></Reference><Reference><Citation>ter Meulen, J. et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med.3, e237 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1483912</ArticleId><ArticleId IdType="pubmed">16796401</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell184, 2332–2347.e16 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7962585</ArticleId><ArticleId IdType="pubmed">33761326</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell183, 1024–1042.e21 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494283</ArticleId><ArticleId IdType="pubmed">32991844</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum, M. et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science375, 864–868 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9427005</ArticleId><ArticleId IdType="pubmed">35076256</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature584, 450–456 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32698192</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerutti, G. et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe29, 819–833.e7 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953435</ArticleId><ArticleId IdType="pubmed">33789084</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson, E. et al. Characterisation of the immune repertoire of a humanised transgenic mouse through immunophenotyping and high-throughput sequencing. Elife12, e81629 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10115447</ArticleId><ArticleId IdType="pubmed">36971345</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney, A. J. et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe29, 463–476.e6 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869748</ArticleId><ArticleId IdType="pubmed">33592168</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls, A. C. et al. Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice. Cell Rep.40, 111299 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9376299</ArticleId><ArticleId IdType="pubmed">35988541</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam, P. S. et al. Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine. Sci. Transl. Med.14, eabq4130 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10466502</ArticleId><ArticleId IdType="pubmed">35976993</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, Y. et al. Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine. Sci. Transl. Med.15, eadg7404 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11032722</ArticleId><ArticleId IdType="pubmed">37163615</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajon, R. et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med.386, 1088–1091 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8809504</ArticleId><ArticleId IdType="pubmed">35081298</ArticleId></ArticleIdList></Reference><Reference><Citation>Gobeil, S. M.-C. et al. Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. Science373, eabi6226 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8611377</ArticleId><ArticleId IdType="pubmed">34168071</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard, A. C. et al. Stabilization of the SARS-CoV-2 receptor binding domain by protein core redesign and deep mutational scanning. Protein Eng. Des. Sel.35, gzac002 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9077414</ArticleId><ArticleId IdType="pubmed">35325236</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed, S. et al. A stabilized, monomeric, receptor binding domain elicits high-titer neutralizing antibodies against all SARS-CoV-2 variants of concern. Front. Immunol.12, 765211 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8695907</ArticleId><ArticleId IdType="pubmed">34956193</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell182, 1295–1310.e20 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418704</ArticleId><ArticleId IdType="pubmed">32841599</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr, T. N. et al. Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains. PLoS Pathog.18, e1010951 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9674177</ArticleId><ArticleId IdType="pubmed">36399443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature614, 521–529 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931576</ArticleId><ArticleId IdType="pubmed">36535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, D. J. et al. Mapping the antigenic and genetic evolution of influenza virus. Science305, 371–376 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15218094</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias, S. et al. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results. Nat. Med.29, 2325–2333 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504066</ArticleId><ArticleId IdType="pubmed">37653342</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias, S. et al. Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19. Nat. Commun.14, 5125 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10447540</ArticleId><ArticleId IdType="pubmed">37612300</ArticleId></ArticleIdList></Reference><Reference><Citation>Usdan, L. et al. A bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 booster in ≥12-year-olds. Clin. Infect. Dis. 10.1093/cid/ciad718 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11093671</ArticleId><ArticleId IdType="pubmed">38016021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu, Z. et al. mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Rep.38, 110514 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8922439</ArticleId><ArticleId IdType="pubmed">35294883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo, M. et al. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat. Immunol.20, 362–372 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380945</ArticleId><ArticleId IdType="pubmed">30742080</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyoglu-Barnum, S. et al. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature592, 623–628 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8269962</ArticleId><ArticleId IdType="pubmed">33762730</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, A. A. et al. Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers. PLoS One16, e0247963 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7932532</ArticleId><ArticleId IdType="pubmed">33661993</ArticleId></ArticleIdList></Reference><Reference><Citation>CEPI. CEPI expands partnership with SK bioscience to develop a ‘variant-proof’ vaccine against SARS-CoV and SARS-CoV-2 variants –. CEPIhttps://cepi.net/news_cepi/cepi-expands-partnership-with-sk-bioscience-to-develop-a-variant-proof-vaccine-against-sars-cov-and-sars-cov-2-variants/ (2021).</Citation></Reference><Reference><Citation>Lempp, F. A. et al. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature10.1038/s41586-021-03925-1 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34464958</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkerke, H. P. et al. Epitope-independent purification of native-like envelope trimers from diverse HIV-1 isolates. J. Virol.90, 9471–9482 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5044855</ArticleId><ArticleId IdType="pubmed">27512064</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, C. et al. hACE2-induced allosteric activation in SARS-CoV versus SARS-CoV-2 spike assemblies revealed by structural dynamics. ACS Infect. Dis.9, 1180–1189 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10228703</ArticleId><ArticleId IdType="pubmed">37166130</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttman, M., Weis, D. D., Engen, J. R. &amp; Lee, K. K. Analysis of overlapped and noisy hydrogen/deuterium exchange mass spectra. J. Am. Soc. Mass Spectrom.24, 1906–1912 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855366</ArticleId><ArticleId IdType="pubmed">24018862</ArticleId></ArticleIdList></Reference><Reference><Citation>Weis, D. D., Engen, J. R. &amp; Kass, I. J. Semi-automated data processing of hydrogen exchange mass spectra using HX-Express. J. Am. Soc. Mass Spectrom.17, 1700–1703 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16931036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauer, M. M. et al. Structural basis for broad coronavirus neutralization. Nat. Struct. Mol. Biol.28, 478–486 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33981021</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls, A. C. et al. SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell185, 872–880.e3 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8769922</ArticleId><ArticleId IdType="pubmed">35123650</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum, M. et al. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science374, 1621–1626 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34751595</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford, K. H. D. et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses12, 513 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7291041</ArticleId><ArticleId IdType="pubmed">32384820</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng, E. C. et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci.32, e4792 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10588335</ArticleId><ArticleId IdType="pubmed">37774136</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>